Your browser doesn't support javascript.
loading
Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
Cao, Ruiyuan; Hu, Hengrui; Li, Yufeng; Wang, Xi; Xu, Mingyue; Liu, Jia; Zhang, Huanyu; Yan, Yunzheng; Zhao, Lei; Li, Wei; Zhang, Tianhong; Xiao, Dian; Guo, Xiaojia; Li, Yuexiang; Yang, Jingjing; Hu, Zhihong; Wang, Manli; Zhong, Wu.
Afiliação
  • Cao R; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
  • Hu H; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, P. R. China.
  • Li Y; University of the Chinese Academy of Sciences, Beijing 100049, P. R. China.
  • Wang X; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, P. R. China.
  • Xu M; University of the Chinese Academy of Sciences, Beijing 100049, P. R. China.
  • Liu J; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, P. R. China.
  • Zhang H; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, P. R. China.
  • Yan Y; University of the Chinese Academy of Sciences, Beijing 100049, P. R. China.
  • Zhao L; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, P. R. China.
  • Li W; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, P. R. China.
  • Zhang T; University of the Chinese Academy of Sciences, Beijing 100049, P. R. China.
  • Xiao D; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
  • Guo X; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
  • Li Y; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
  • Yang J; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
  • Hu Z; Guoke Excellence (Beijing) Medicine Technology Research Co., Ltd., Beijing 100176, P. R. China.
  • Wang M; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
  • Zhong W; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
ACS Infect Dis ; 6(9): 2524-2531, 2020 09 11.
Article em En | MEDLINE | ID: mdl-32786284
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 3_ND / 4_TD Problema de saúde: 3_malaria / 4_pneumonia Assunto principal: Antivirais / Pneumonia Viral / Infecções por Coronavirus / Artemisininas / Betacoronavirus Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: ACS Infect Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 3_ND / 4_TD Problema de saúde: 3_malaria / 4_pneumonia Assunto principal: Antivirais / Pneumonia Viral / Infecções por Coronavirus / Artemisininas / Betacoronavirus Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: ACS Infect Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China